221006-66-2

Basic information

• Product Name: 3-PHENOXYBENZENEBORONIC ACID
• Synonyms: 3-PHENOXYPHNEYLBORONIC ACID;3-PHENOXYBENZENEBORONIC ACID;3-Phenoxyphenylboronic acid;3-Phenoxybenzeneboronic acid, 97+%;B-(3-phenoxy-phenyl)boronic acid;(3-Phenoxyphenyl)
• CAS NO: 221006-66-2
• Molecular Formula: C₁₂H₁₁BO₃
• Molecular Weight: 214.02
• Mol File: 221006-66-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 138-143℃
• Boiling Point: 391.1±44.0 °C(Predicted)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• Solubility: Slightly soluble.
• PKA: 7.82±0.10(Predicted)
• CAS DataBase Reference: 3-PHENOXYBENZENEBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PHENOXYBENZENEBORONIC ACID(221006-66-2)
• EPA Substance Registry System: 3-PHENOXYBENZENEBORONIC ACID(221006-66-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 221006-66-2(Hazardous Substances Data)

Usage

Uses

The extensive use of products containing PBDEs has resulted in the release of 3-Phenoxybenzeneboronic acid.

Upstream product

• 6876-00-2 3-bromodiphenyl ether 

Downstream Products

• 26076-68-6 2-(3-phenoxy-phenyl)-[1,3,6,2]dioxazaborocane 
• 576169-45-4 ethyl 3-(3-phenoxyphenyl)-2-furancarboxylate 
• 864772-18-9 4,4,5,5-tetramethyl-2-(3-phenoxyphenyl)-1,3,2-dioxaborolane 
• 713-68-8 meta-phenoxyphenol 

Relevant articles and documents

Anthracene compound, preparing method of anthracene compound and organic light-emitting device

The invention provides an anthracene compound. The anthracene compound has a structure in the formula (I), wherein Q is the C1-60 alkyl group or the C6-60 aryl group or the C5-60 condensed ring group or the C5-60 heterocyclic group; Ar is the C6-60 aryl group or the C5-60 condensed ring group or the C5-60 heterocyclic group; and Ar1 is H, the C1-60 alkyl group, the C1-60 alkoxy group, the C1-60 ether group, the C6-60 aryl group, the C6-60 condensed ring group, the C6-60 heterocyclic group and the C6-60 arylamine group. Compared with the prior art, the anthracene compound is connected with an aromatic compound through anthracene, and the Q, Ar and Ar1 groups are introduced, so that a device emits blue light after the organic compound is applied to the organic light-emitting device; and meanwhile, the means that the above groups are used for adjusting the light-emitting wavelength is adopted, the light-emitting efficiency of the organic light-emitting device is high, and the service life is long.

Multiple C-H activations to construct biologically active molecules in a process completely free of organohalogen and organometallic components

(Chemical Equation Presented) Step by step: Highly selective cross dehydrogenase arylation of acetanilides was developed to construct biaryls under mild condition. With this method, different aryl C-H bonds were activated in sequential reactions to construct functionalized carbazoles (see scheme), which are present as key structural units in various biological molecules and organic optical materials.

2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula(I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof, methods for producing them and pharmaceutical compositions containing them: wherein A is a group represented by Formula (a) or the like: (wherein either R4 or R5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R1 or R2 represents a group: -D-(X)m-R6 or the like, and the other represents a group: -E-(Y)n-R7, hydrogen atom, aryl or the like; R3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent 0 or the like; R6 and R7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted. Such compounds exhibit a potent antagonistic activity on glucagon receptor and are of use as preventive and/or therapeutic agents for symptoms and diseases in which glucagon is involved.